MDGL · Madrigal Pharmaceuticals, Inc. · Documents

Jun 27

Current report 8-K Events of Jun 25

Director or officer change, or executive pay, Shareholder vote results

May 7

Current report 8-K

Financial results

May 7

Earnings call

Q1 2024 earnings call

May 7

Current report 8-K

Entered into a material agreement, Ended a material agreement, Other events

May 7

Quarterly report 10-Q FY2024 Q1, ended Mar 31

Quarterly report for FY2024 Q1

Revenue $0 Net loss $147.54M Diluted EPS -$7.38

May 7

Registration statement S-3ASR

Registration statement

Apr 29

Proxy statement DEF 14A Meeting Jun 25, 2024

Proxy statement

Apr 29

Annual report to holders ARS

Annual report to holders

Apr 29

Proxy statement DEFA14A

Proxy statement

Apr 2

Current report 8-K Events of Mar 27

Other events

Mar 20

Current report 8-K Events of Mar 18

Entered into a material agreement

Mar 15

Current report 8-K Events of Mar 14

Regulation FD disclosure, Other events

Feb 28

Current report 8-K

Financial results

Feb 28

Current report 8-K Events of Feb 22

Director or officer change, or executive pay

Feb 28

Annual report 10-K Ended Dec 31

Annual report for the period ended Dec 31, 2023

Revenue $0 Net loss $373.63M Diluted EPS -$19.99

Jan 8

Current report 8-K

Other events

Nov 6

Current report 8-K

Financial results

Nov 6

Quarterly report 10-Q FY2023 Q3, ended Sep 30

Quarterly report for FY2023 Q3

Net loss $98.74M Diluted EPS -$5.34

Oct 2

Current report 8-K Events of Sep 28

Entered into a material agreement

Sep 25

Current report 8-K Events of Sep 20

Director or officer change, or executive pay

Sep 14

Current report 8-K Events of Sep 8

Director or officer change, or executive pay

Sep 13

Current report 8-K Events of Sep 12

Other events

Sep 13

Current report 8-K Events of Sep 7

Director or officer change, or executive pay

Aug 8

Current report 8-K

Financial results

Aug 8

Quarterly report 10-Q FY2023 Q2, ended Jun 30

Quarterly report for FY2023 Q2

Net loss $85.8M Diluted EPS -$4.69

Jul 17

Current report 8-K

Other events

Jun 30

Current report 8-K

Other events

Jun 20

Current report 8-K Events of Jun 15

Charter or bylaw amendment, or fiscal year change, Shareholder vote results

Jun 20

Current report 8-K Events of Jun 15

Director or officer change, or executive pay

May 9

Current report 8-K

Financial results

May 9

Current report 8-K

Entered into a material agreement

May 9

Quarterly report 10-Q FY2023 Q1, ended Mar 31

Quarterly report for FY2023 Q1

Revenue $0 Net loss $76.9M Diluted EPS -$4.23

May 1

Proxy statement DEF 14A

Proxy statement

May 1

Proxy statement DEFA14A

Proxy statement

Apr 21

Proxy statement PRE 14A

Proxy statement

Mar 3

Annual report 10-K/A FY2022, ended Dec 31

Annual report for FY2022

Revenue $0 Net loss $295.35M Diluted EPS -$17.23

Feb 23

Current report 8-K

Financial results

Feb 23

Annual report 10-K FY2022, ended Dec 31

Annual report for FY2022

Revenue $0 Net loss $295.35M Diluted EPS -$17.23

Feb 9

Current report 8-K Events of Feb 3

Entered into a material agreement, New debt or off-balance-sheet obligation, Unregistered sale of equity

Jan 10

Current report 8-K Events of Jan 6

Other events

Dec 23

Current report 8-K Events of Dec 19

Entered into a material agreement, Charter or bylaw amendment, or fiscal year change, Regulation FD disclosure, Other events

Dec 19

Current report 8-K

Regulation FD disclosure, Other events

Nov 3

Current report 8-K

Financial results

Nov 3

Quarterly report 10-Q FY2022 Q3, ended Sep 30

Quarterly report for FY2022 Q3

Net loss $81.2M Diluted EPS -$4.75

Aug 4

Current report 8-K

Financial results

Aug 4

Quarterly report 10-Q FY2022 Q2, ended Jun 30

Quarterly report for FY2022 Q2

Net loss $70.73M Diluted EPS -$4.14

Jun 17

Current report 8-K Events of Jun 15

Shareholder vote results

May 9

Current report 8-K

Financial results

May 9

Earnings call

Q1 2022 earnings call

May 9

Current report 8-K

Entered into a material agreement, New debt or off-balance-sheet obligation, Unregistered sale of equity